Trend in Survival Benefit with a Combination of Spartalizumab Plus Dabrafenib and Trametinib Over Targeted Therapy Alone for BRAF V600-mutated Metastatic Melanoma By Ogkologos - August 27, 2026 96 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMBI-I study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge Adjuvant fractionated radiotherapy significantly improves DFS in patients with atypical meningioma who have undergone complete surgical resection MOST POPULAR News digest – dinosaur bone cancer, YouTube junk food ad ban... August 8, 2020 FDA Approves Azacitidine Tablets for Acute Myeloid Leukaemia September 4, 2020 FDA Approves Updated Drug Labelling Including New Indications and Dosing Regimens... January 9, 2023 Consistent Efficacy Benefit with Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients... April 30, 2024 Load more HOT NEWS Why haven’t we cured cancer? – That Cancer Conversation Sugar Compound Found in Breast Milk May Help Ease Chemotherapy Side... McDonald’s Customer Buys Breakfast For Mom And Soldier Son, Unaware Of... 5 Tips to Move Beyond the Bedside
